156 related articles for article (PubMed ID: 25732128)
1. Faecal calprotectin as a marker for oesophago-gastric cancer.
Vincent Z; Hornby S; Ball S; Sanders G; Ayling RM
Ann Clin Biochem; 2015 Nov; 52(Pt 6):660-4. PubMed ID: 25732128
[TBL] [Abstract][Full Text] [Related]
2. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers.
Joshi S; Lewis SJ; Creanor S; Ayling RM
Ann Clin Biochem; 2010 May; 47(Pt 3):259-63. PubMed ID: 19740914
[TBL] [Abstract][Full Text] [Related]
3. Faecal calprotectin concentrations in gastrointestinal diseases.
Wang S; Wang Z; Shi H; Heng L; Juan W; Yuan B; Wu X; Wang F
J Int Med Res; 2013 Aug; 41(4):1357-61. PubMed ID: 23723365
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis.
Johnson MW; Maestranzi S; Duffy AM; Dewar DH; Forbes A; Bjarnason I; Sherwood RA; Ciclitira P; Nicholls JR
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):174-9. PubMed ID: 18301296
[TBL] [Abstract][Full Text] [Related]
5. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Summerton CB; Longlands MG; Wiener K; Shreeve DR
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
[TBL] [Abstract][Full Text] [Related]
8. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
Jeffery J; Lewis SJ; Ayling RM
Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
[TBL] [Abstract][Full Text] [Related]
9. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
10. Role of faecal calprotectin as non-invasive marker of intestinal inflammation.
Costa F; Mumolo MG; Bellini M; Romano MR; Ceccarelli L; Arpe P; Sterpi C; Marchi S; Maltinti G
Dig Liver Dis; 2003 Sep; 35(9):642-7. PubMed ID: 14563186
[TBL] [Abstract][Full Text] [Related]
11. Correlation between faecal calprotectin and magnetic resonance imaging (MRI) in the evaluation of inflammatory pattern in Crohn's disease.
Zippi M; Al Ansari N; Siliquini F; Severi C; Kagarmanova A; Maffia C; Parlanti S; Garbarino V; Maccioni F
Clin Ter; 2010; 161(2):e53-6. PubMed ID: 20499020
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies.
Khoshbaten M; Pishahang P; Nouri M; Lashkari A; Alizadeh M; Rostami-Nejad M
Asian Pac J Cancer Prev; 2014; 15(4):1667-70. PubMed ID: 24641386
[TBL] [Abstract][Full Text] [Related]
13. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
[TBL] [Abstract][Full Text] [Related]
14. High faecal calprotectin levels in healthy, exclusively breast-fed infants.
Savino F; Castagno E; Calabrese R; Viola S; Oggero R; Miniero R
Neonatology; 2010 Jun; 97(4):299-304. PubMed ID: 19887860
[TBL] [Abstract][Full Text] [Related]
15. Mass Spectrometric Analysis of Exhaled Breath for the Identification of Volatile Organic Compound Biomarkers in Esophageal and Gastric Adenocarcinoma.
Kumar S; Huang J; Abbassi-Ghadi N; Mackenzie HA; Veselkov KA; Hoare JM; Lovat LB; Španěl P; Smith D; Hanna GB
Ann Surg; 2015 Dec; 262(6):981-90. PubMed ID: 25575255
[TBL] [Abstract][Full Text] [Related]
16. Paediatric reference ranges for faecal calprotectin: a UK study.
Davidson F; Lock RJ
Ann Clin Biochem; 2017 Mar; 54(2):214-218. PubMed ID: 27141011
[TBL] [Abstract][Full Text] [Related]
17. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
19. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.
Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
J Crohns Colitis; 2014 Sep; 8(9):1022-9. PubMed ID: 24566170
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]